Like_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696124060,"tweetId":"696124060","gmtCreate":1640652781800,"gmtModify":1640652812638,"author":{"id":3572077804076143,"idStr":"3572077804076143","authorId":3572077804076143,"authorIdStr":"3572077804076143","name":"Yappy","avatar":"https://static.tigerbbs.com/ab4d89913ade03f15c782b99132ba22f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":53,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Like</body></html>","htmlText":"<html><head></head><body>Like</body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696124060","repostId":1156481741,"repostType":4,"repost":{"id":"1156481741","kind":"news","pubTimestamp":1640652473,"share":"https://www.laohunote.com/m/news/1156481741?lang=zh_CN&edition=full","pubTime":"2021-12-28 08:47","market":"us","language":"en","title":"Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?<blockquote>FDA 批准其 Covid 药丸后，默克股票是买入还是卖出？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156481741","media":"Investors","summary":"The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Me","content":"The Food and Drug Administration authorized&nbsp;Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.<blockquote>食品药品监督管理局授权默克（MRK）抗病毒Covid药丸，莫努匹拉韦。但默克股票仍面临压力。</blockquote> The FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.<blockquote>当其他选择不可用或不合适时，FDA授权Ridgeback Biotherapeutics合作的药丸紧急使用。辉瑞(PFE) 还获得了其两种药片疗法 Paxlovid 的授权。Paxlovid在临床试验中被证明更有效。此外，molnupiravir具有癌症风险，并可能导致未出生儿童出生缺陷。</blockquote> Merck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.<blockquote>当患者在症状出现五天内开始治疗时，默克公司的molnupiravir可将与Covid相关的住院或死亡风险降低30%。对于在症状出现三天内开始治疗的患者，Paxlovid将相同的风险降低了89%。</blockquote> Merck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.<blockquote>默克股价已远高于 11 月份创下的高点。乐观地，该公司第三季度的业绩超出了预期，并提供了乐观的 2021 年前景，其中不包括抗病毒药物的潜在影响。莫努匹拉韦在英国和日本也是允许的。</blockquote> Merck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.<blockquote>默沙东预计今年将生产1000万个疗程的莫努匹拉韦，2022年将生产至少2000万个疗程。它与包括美国在内的全球30多个国家签订了供应协议。</blockquote> So, all in all, is Merck stock a buy or a sell right now?<blockquote>那么，总而言之，默克股票现在是买入还是卖出？</blockquote> Merck Stock Fundamentals: Sales Top<blockquote>默克股票基本面：销售榜首</blockquote> During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.<blockquote>第三季度，调整后收益攀升 28%，达到每股 1.75 美元，销售额飙升 20%，达到 131.5 亿美元。这两项指标都超出了预期。</blockquote> Merck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.<blockquote>默克公司还提供了指导器官（OGN）衍生产品。这家制药公司将全年预期上调至调整后每股利润 5.65-5.70 美元，销售额从 474 亿美元上调至 479 亿美元。这两项指标都超出了预期。它们不包括莫努匹拉韦在美国或欧洲获得授权的潜力。</blockquote> The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.<blockquote>该公司最大的单一药物仍然是癌症治疗药物 Keytruda。Keytruda 占第三季度总销售额的三分之一以上。Keytruda 销售额增长 22%，达到 45.3 亿美元。其人乳头瘤病毒疫苗 Gardasil 的销售额飙升 68%，达到 19.9 亿美元。</blockquote> But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.<blockquote>但糖尿病药物 Januvia 的收入下降了 1%，至 13.4 亿美元。默克公司报告称，随着新冠疫苗在美国获得优先权，其肺炎疫苗 Pneumovax 23 的销量下降了 26%。</blockquote> Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.<blockquote>总体而言，第三季度的指标符合 CAN SLIM 投资规则，该规则建议投资者寻找最近季度增长率为 20%-25% 或更好的公司。</blockquote> In the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.<blockquote>FactSet 调查的分析师预计，本季度默克每股收益为 1.52 美元，销售额为 131.6 亿美元。按年计算，盈利将激增约 21%，销售额将增长 5% 以上。</blockquote> What Do Annual Metrics Say About Merck?<blockquote>年度指标说明了默克公司的什么？</blockquote> As Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.<blockquote>截至12月27日，默克股价今年小幅下跌。股价最近触及至少三十年来的高点，但此后一直暴跌。</blockquote> Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.<blockquote>去年，默克公司的销售额增长了 2.5%，达到 479.9 亿美元。这比 2019 年 11% 的增长率有所放缓。</blockquote> For 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.<blockquote>分析师预计 2021 年销售额将小幅增长至 484.4 亿美元。收入预计将增长 2.8%，达到每股 5.82 美元。此前，2020 年增长了 14%。</blockquote> The stock ranks 6th by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.<blockquote>该股在制药公司行业组中的综合评级排名第六。在《投资者商业日报》追踪的 197 个集团中，由 33 家公司组成的医疗伦理药物集团排名第 51 位。</blockquote> Technical Analysis Of The Pharmaceutical Company<blockquote>医药公司技术分析</blockquote> Merck stock has a&nbsp;Composite Rating&nbsp;of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.<blockquote>默克股票的综合评级为 81 分（满分 99 分）。CR 是衡量股票过去 12 个月关键增长指标的指标。这使得默克股票在所有股票中排名前 19%，无论行业类别如何。</blockquote> Shares also have a&nbsp;Relative Strength Rating&nbsp;of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.<blockquote>该股的相对强度评级也为 57，反映了默克股票 12 个月的表现。这意味着该制药股的表现低于所有股票的前三分之一。</blockquote> It's also key to watch chart patterns. Merck stock broke out of a&nbsp;flat base&nbsp;with abuy point&nbsp;at 79.33 on Oct. 1, according to&nbsp;MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are&nbsp;encouraged to sell&nbsp;when a stock is 7%-8% below its entry.<blockquote>观察图表模式也很关键。根据 MarketSmith.com 的数据，10 月 1 日，默克股价打破了平盘，abuy 点为 79.33。但股价较 11 月 30 日的入场价下跌了 7%。这引发了卖出信号。当股票低于入场价 7%-8% 时，鼓励投资者卖出。</blockquote> Merck stock also recently undercut its&nbsp;50-day&nbsp;and&nbsp;200-day&nbsp;moving averages. Both are sell signals.<blockquote>默克股价最近也跌破了 50 天和 200 天移动平均线。两者都是卖出信号。</blockquote> Merck Stock News: Merck Grabs Covid Deal<blockquote>默克股票新闻：默克获得新冠交易</blockquote> Merck's molnupiravir is now authorized in the U.S., U.K. and Japan.<blockquote>默沙东的molnupiravir现已在美国、英国和日本获得授权。</blockquote> In addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.<blockquote>除了默沙东和辉瑞，Atea制药（阿韦）和Enanta制药（ENTA）研究口服Covid药物。罗氏(RHHBY) 最近退出了与 Atea 就 Covid 抗病毒药物达成的协议。</blockquote> Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.<blockquote>分析人士表示，与抗体药物相比，这些药丸可以为新冠病毒的非住院治疗提供更简单的途径再生元制药（雨），礼来（LLY）和生物技术（来源）。抗体药物必须由医疗保健专业人员给予。</blockquote> But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.<blockquote>但有人担心molnupiravir的工作方式可能会将突变引入未出生婴儿的DNA。因此，FDA顾问在是否建议孕妇使用它的问题上犹豫不决。</blockquote> Bearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and&nbsp;Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.<blockquote>悲观的是，FDA 暂停了一项测试艾滋病毒预防药物 islatravir 的研究。几名患者显示关键免疫细胞减少。默克和吉利德科学（GILD）还决定停止在HIV患者中测试islatravir和Gilead的lenacapavir方案。</blockquote> Merck also recently finished acquiring Acceleron.<blockquote>默克公司最近还完成了对 Acceleron 的收购。</blockquote> In early March, President Joe Biden announced Merck would helpJohnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.<blockquote>三月初，乔·拜登总统宣布默克将提供帮助强生公司（JNJ）生产新冠疫苗。默克将从生物医学高级研究与发展局获得 2.688 亿美元，以帮助扩大设施空间。</blockquote> Is Merck Stock A Buy Now?<blockquote>默克股票现在值得买入吗？</blockquote> Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.<blockquote>根据 CAN SLIM 投资规则，不，默克股票现在不值得购买。股价已经扭转了早些时候的突破，并引发了几个卖出信号。</blockquote> There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.<blockquote>还有进一步的警告。默克公司第三季度的销售额和盈利均符合 CAN SLIM 指导方针。预计本季度销售额不会达到这一里程碑。</blockquote> Still, big stocks like Merck can add gains without hitting massive growth streaks.<blockquote>尽管如此，像默克这样的大盘股可以在不实现大幅增长的情况下增加涨幅。</blockquote>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?<blockquote>FDA 批准其 Covid 药丸后，默克股票是买入还是卖出？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Merck Stock A Buy Or Sell After FDA Authorizes Its Covid Pill?<blockquote>FDA 批准其 Covid 药丸后，默克股票是买入还是卖出？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nInvestors2021-12-28 08:47\n\n</h4>\n</header>\n<article>\nThe Food and Drug Administration authorized&nbsp;Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.<blockquote>食品药品监督管理局授权默克（MRK）抗病毒Covid药丸，莫努匹拉韦。但默克股票仍面临压力。</blockquote> The FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.<blockquote>当其他选择不可用或不合适时，FDA授权Ridgeback Biotherapeutics合作的药丸紧急使用。辉瑞(PFE) 还获得了其两种药片疗法 Paxlovid 的授权。Paxlovid在临床试验中被证明更有效。此外，molnupiravir具有癌症风险，并可能导致未出生儿童出生缺陷。</blockquote> Merck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.<blockquote>当患者在症状出现五天内开始治疗时，默克公司的molnupiravir可将与Covid相关的住院或死亡风险降低30%。对于在症状出现三天内开始治疗的患者，Paxlovid将相同的风险降低了89%。</blockquote> Merck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.<blockquote>默克股价已远高于 11 月份创下的高点。乐观地，该公司第三季度的业绩超出了预期，并提供了乐观的 2021 年前景，其中不包括抗病毒药物的潜在影响。莫努匹拉韦在英国和日本也是允许的。</blockquote> Merck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.<blockquote>默沙东预计今年将生产1000万个疗程的莫努匹拉韦，2022年将生产至少2000万个疗程。它与包括美国在内的全球30多个国家签订了供应协议。</blockquote> So, all in all, is Merck stock a buy or a sell right now?<blockquote>那么，总而言之，默克股票现在是买入还是卖出？</blockquote> Merck Stock Fundamentals: Sales Top<blockquote>默克股票基本面：销售榜首</blockquote> During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.<blockquote>第三季度，调整后收益攀升 28%，达到每股 1.75 美元，销售额飙升 20%，达到 131.5 亿美元。这两项指标都超出了预期。</blockquote> Merck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.<blockquote>默克公司还提供了指导器官（OGN）衍生产品。这家制药公司将全年预期上调至调整后每股利润 5.65-5.70 美元，销售额从 474 亿美元上调至 479 亿美元。这两项指标都超出了预期。它们不包括莫努匹拉韦在美国或欧洲获得授权的潜力。</blockquote> The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.<blockquote>该公司最大的单一药物仍然是癌症治疗药物 Keytruda。Keytruda 占第三季度总销售额的三分之一以上。Keytruda 销售额增长 22%，达到 45.3 亿美元。其人乳头瘤病毒疫苗 Gardasil 的销售额飙升 68%，达到 19.9 亿美元。</blockquote> But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.<blockquote>但糖尿病药物 Januvia 的收入下降了 1%，至 13.4 亿美元。默克公司报告称，随着新冠疫苗在美国获得优先权，其肺炎疫苗 Pneumovax 23 的销量下降了 26%。</blockquote> Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.<blockquote>总体而言，第三季度的指标符合 CAN SLIM 投资规则，该规则建议投资者寻找最近季度增长率为 20%-25% 或更好的公司。</blockquote> In the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.<blockquote>FactSet 调查的分析师预计，本季度默克每股收益为 1.52 美元，销售额为 131.6 亿美元。按年计算，盈利将激增约 21%，销售额将增长 5% 以上。</blockquote> What Do Annual Metrics Say About Merck?<blockquote>年度指标说明了默克公司的什么？</blockquote> As Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.<blockquote>截至12月27日，默克股价今年小幅下跌。股价最近触及至少三十年来的高点，但此后一直暴跌。</blockquote> Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.<blockquote>去年，默克公司的销售额增长了 2.5%，达到 479.9 亿美元。这比 2019 年 11% 的增长率有所放缓。</blockquote> For 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.<blockquote>分析师预计 2021 年销售额将小幅增长至 484.4 亿美元。收入预计将增长 2.8%，达到每股 5.82 美元。此前，2020 年增长了 14%。</blockquote> The stock ranks 6th by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.<blockquote>该股在制药公司行业组中的综合评级排名第六。在《投资者商业日报》追踪的 197 个集团中，由 33 家公司组成的医疗伦理药物集团排名第 51 位。</blockquote> Technical Analysis Of The Pharmaceutical Company<blockquote>医药公司技术分析</blockquote> Merck stock has a&nbsp;Composite Rating&nbsp;of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.<blockquote>默克股票的综合评级为 81 分（满分 99 分）。CR 是衡量股票过去 12 个月关键增长指标的指标。这使得默克股票在所有股票中排名前 19%，无论行业类别如何。</blockquote> Shares also have a&nbsp;Relative Strength Rating&nbsp;of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.<blockquote>该股的相对强度评级也为 57，反映了默克股票 12 个月的表现。这意味着该制药股的表现低于所有股票的前三分之一。</blockquote> It's also key to watch chart patterns. Merck stock broke out of a&nbsp;flat base&nbsp;with abuy point&nbsp;at 79.33 on Oct. 1, according to&nbsp;MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are&nbsp;encouraged to sell&nbsp;when a stock is 7%-8% below its entry.<blockquote>观察图表模式也很关键。根据 MarketSmith.com 的数据，10 月 1 日，默克股价打破了平盘，abuy 点为 79.33。但股价较 11 月 30 日的入场价下跌了 7%。这引发了卖出信号。当股票低于入场价 7%-8% 时，鼓励投资者卖出。</blockquote> Merck stock also recently undercut its&nbsp;50-day&nbsp;and&nbsp;200-day&nbsp;moving averages. Both are sell signals.<blockquote>默克股价最近也跌破了 50 天和 200 天移动平均线。两者都是卖出信号。</blockquote> Merck Stock News: Merck Grabs Covid Deal<blockquote>默克股票新闻：默克获得新冠交易</blockquote> Merck's molnupiravir is now authorized in the U.S., U.K. and Japan.<blockquote>默沙东的molnupiravir现已在美国、英国和日本获得授权。</blockquote> In addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.<blockquote>除了默沙东和辉瑞，Atea制药（阿韦）和Enanta制药（ENTA）研究口服Covid药物。罗氏(RHHBY) 最近退出了与 Atea 就 Covid 抗病毒药物达成的协议。</blockquote> Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.<blockquote>分析人士表示，与抗体药物相比，这些药丸可以为新冠病毒的非住院治疗提供更简单的途径再生元制药（雨），礼来（LLY）和生物技术（来源）。抗体药物必须由医疗保健专业人员给予。</blockquote> But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.<blockquote>但有人担心molnupiravir的工作方式可能会将突变引入未出生婴儿的DNA。因此，FDA顾问在是否建议孕妇使用它的问题上犹豫不决。</blockquote> Bearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and&nbsp;Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.<blockquote>悲观的是，FDA 暂停了一项测试艾滋病毒预防药物 islatravir 的研究。几名患者显示关键免疫细胞减少。默克和吉利德科学（GILD）还决定停止在HIV患者中测试islatravir和Gilead的lenacapavir方案。</blockquote> Merck also recently finished acquiring Acceleron.<blockquote>默克公司最近还完成了对 Acceleron 的收购。</blockquote> In early March, President Joe Biden announced Merck would helpJohnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.<blockquote>三月初，乔·拜登总统宣布默克将提供帮助强生公司（JNJ）生产新冠疫苗。默克将从生物医学高级研究与发展局获得 2.688 亿美元，以帮助扩大设施空间。</blockquote> Is Merck Stock A Buy Now?<blockquote>默克股票现在值得买入吗？</blockquote> Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.<blockquote>根据 CAN SLIM 投资规则，不，默克股票现在不值得购买。股价已经扭转了早些时候的突破，并引发了几个卖出信号。</blockquote> There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.<blockquote>还有进一步的警告。默克公司第三季度的销售额和盈利均符合 CAN SLIM 指导方针。预计本季度销售额不会达到这一里程碑。</blockquote> Still, big stocks like Merck can add gains without hitting massive growth streaks.<blockquote>尽管如此，像默克这样的大盘股可以在不实现大幅增长的情况下增加涨幅。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220\">Investors</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.investors.com/news/technology/merck-stock-buy-now/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156481741","content_text":"The Food and Drug Administration authorized Merck's (MRK) antiviral Covid pill, molnupiravir. But Merck stock remains under pressure.\nThe FDA authorized the Ridgeback Biotherapeutics-partnered pill for emergency use when other options aren't available or appropriate.Pfizer(PFE) also gained authorization for its two-pill regimen, Paxlovid. Paxlovid proved more effective in clinical testing. Further, molnupiravir carries a cancer risk and could lead to birth defects in unborn children.\nMerck's molnupiravir cut the risk of Covid-related hospitalizations or death by 30% when patients began treatment within five days of symptoms appearing. Paxlovid reduced the same risk by 89% for patients who began treatment within three days of symptom onset.\nMerck stock is well off highs it achieved in November. Bullishly, the company beat third-quarter expectations and offered an upbeat 2021 outlook that didn't include the potential impact of the antiviral pill. Molnupiravir is also allowed in the U.K. and Japan.\nMerck expects to produce 10 million courses of molnupiravir this year and at least 20 million in 2022. It has supply agreements in place with more than 30 countries worldwide, including the U.S.\nSo, all in all, is Merck stock a buy or a sell right now?\nMerck Stock Fundamentals: Sales Top\nDuring the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.\nMerck also provided guidance following its Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.\nThe company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.\nBut revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.\nOverall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.\nIn the current quarter, analysts polled by FactSet expect Merck to earn $1.52 per share on $13.16 billion in sales. On a year-over-year basis, earnings would surge about 21% and sales would rise north of 5%.\nWhat Do Annual Metrics Say About Merck?\nAs Dec. 27, Merck stock was down slightly for the year. Shares recently hit at least a three-decade high, but have since tumbled.\nLast year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.\nFor 2021, analysts expect sales to rise a fraction to $48.44 billion. Income is projected to inch 2.8% higher to $5.82 a share. That follows 14% growth in 2020.\nThe stock ranks 6th by Composite Rating in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks No. 51 out of 197 groups tracked by Investor's Business Daily.\nTechnical Analysis Of The Pharmaceutical Company\nMerck stock has a Composite Rating of 81 out of a best-possible 99. The CR is a measure of a stock's key growth metrics over the past 12 months. This puts Merck stock within the top 19% of all stocks, regardless of industry group.\nShares also have a Relative Strength Rating of 57, reflecting the 12-month performance of Merck stock. This means the pharmaceutical stock ranks beneath the top one-third all stocks in terms of performance.\nIt's also key to watch chart patterns. Merck stock broke out of a flat base with abuy point at 79.33 on Oct. 1, according to MarketSmith.com. But shares fell as much as 7% below their entry on Nov. 30. That triggered a sell signal. Investors are encouraged to sell when a stock is 7%-8% below its entry.\nMerck stock also recently undercut its 50-day and 200-day moving averages. Both are sell signals.\nMerck Stock News: Merck Grabs Covid Deal\nMerck's molnupiravir is now authorized in the U.S., U.K. and Japan.\nIn addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.\nAnalysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.\nBut there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.\nBearishly, the FDA placed a study testing an HIV prevention drug, islatravir, on clinical hold. Several patients showed decreased in key immune cells. Merck and Gilead Sciences(GILD) also decided to stop testing a regimen of islatravir and Gilead's lenacapavir in HIV patients.\nMerck also recently finished acquiring Acceleron.\nIn early March, President Joe Biden announced Merck would helpJohnson & Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.\nIs Merck Stock A Buy Now?\nBased on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.\nThere are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.\nStill, big stocks like Merck can add gains without hitting massive growth streaks.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":3690,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696124060"}